Developing a vaccine against congenital CMV infection: what have we learned from animal models? Where should we go next?

Author： Schleiss Mark R  

Publisher： Future Medicine

ISSN： 1746-0794

Source： Future Virology, Vol.8, Iss.12, 2013-12, pp. : 1161-1182

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Genetic basis of susceptibility to drug-induced liver injury: what have we learned and where do we go from here?

By Urban Thomas J   Goldstein David B   Watkins Paul B  

Pharmacogenomics, Vol. 13, Iss. 7, 2012-05 ,pp. : 735-738

Future Medicine

Access to resources Recommend Favorite

Myc - What We have Learned from Flies

By  

Current Drug Targets, Vol. 10, Iss. 7, 2009-07 ,pp. : 590-601

Bentham Science Publishers

Access to resources Recommend Favorite

Novel Non-Steroidal Anti-Inflammatory Drugs: What we have Learned from Animal Studies

By  

Current Drug Targets. Inflammation & Allergy, Vol. 3, Iss. 1, 2004-03 ,pp. : 43-61

Bentham Science Publishers

Access to resources Recommend Favorite

Anti-Tumour Effects of Bisphosphonates - What have we Learned from In Vivo Models?

By  

Current Cancer Drug Targets, Vol. 9, Iss. 7, 2009-11 ,pp. : 807-823

Bentham Science Publishers

Access to resources Recommend Favorite

Paediatric Pharmacy in Australia: Where Have We Come From and Where Do We Need To Go?

By  

JOURNAL OF PHARMACY PRACTICE AND RESEARCH, Vol. 43, Iss. 1, 2013-03 ,pp. : 45-48

John Wiley & Sons Inc

Access to resources Recommend Favorite